Claims for Patent: 4,195,085

Summary for Patent: 4,195,085

Title:	Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate
Abstract:	Antiglaucoma compositions containing t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate and method of treating elevated intraocular pressure.
Inventor(s):	Stone; Clement A. (Blue Bell, PA)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Application Number:	05/937,696
Patent Claims:	1. A method for treating glaucoma and for lowering intraocular pressure which comprises topically applying to the glaucomatous eye an intraocular pressure lowering effective amount of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate. 2. A method according to claim 1 wherein the t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol is administered in a water soluble polymeric insert. 3. A method according to claim 2 wherein the polymer is hydroxypropylcellulose. 4. A method according to claim 1 wherein the t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol is administered as a 0.01 to 5% solution of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol in an ophthalmologically acceptable carrier. 5. An ophthalmic composition for the topical treatment of glaucoma comprising in solution an intraocular pressure lowering effective amount of t-butylamino-3-(4-morpholino-1,2,5-thiadiazole-3-yloxy)-2-propanol hydrogen maleate and a liquid ophthlamic carrier. 6. A composition according to claim 5 wherein the solution is from 0.01 to 5% t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate. 7. A composition according to claim 5 wherein the solution is from 0.5 to 2% t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate.